It is worth noting that missense mutations in the critical domain of EAAT2 are able to change the direction of glutamate flow, i.e., G82R and L85P in EAAT2 (37), which suggests that genetic testing should be performed prior to EAAT2-based therapy in patients with epilepsy to avoid more severe excitotoxicity. Here, SLC1A2 is linked to epilepsy.